Yanming Wang, PhD

Department of Radiology
School of Medicine
Secondary Faculty
Department of Chemistry
College of Arts and Sciences
Department of Radiopharmaceutical Division
Case Center for Imaging Research
School of Medicine
Cancer Imaging Program
Case Comprehensive Cancer Center

Research Information

Research Interests

  • Molecular imaging in neurological diseases and cancer
  • Radiopharmaceuticals for PET
  • Contrast agents for MRI
  • Fluorescent probes for Optical Imaging
  • Alzheimer’s disease
  • Multiple sclerosis
  • Autism
  • Drug discovery and development

Research Projects

Since 1998, Dr. Wang’s research has been focused on the development of molecular probes for imaging-guided diagnosis and efficacy evaluation of therapeutic treatments in neurological diseases and cancer, which are based on a variety of imaging modalities including positron emission tomography (PET), single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), multiphoton microscopy (SPECT), and near-infrared fluorescent imaging (NIRF). He has developed several imaging agents targeting some important pathological processes such as amyloid deposition in Alzheimer’s disease and aging, myelin damage and repair in multiple sclerosis, DNA damage and repair as well as MET receptor expression in cancer. He was one of the joint inventors of PIB, an amyloid-imaging agent that has now been widely used in clinical trials worldwide. He is also noted for his work on longitudinal imaging of demyelination/remyelination based on multiple imaging modalities. As Director of Radiopharmaceutical Research at Case Western Reserve University, Dr. Wang provides radiolabeled agents for nuclear imaging.


Doctor of Philosophy
Swiss Federal Institute of Technology

Residencies, Internships and Fellowships

Postdoctoral Research
Duke University